Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Atopic Dermatitis
NCT01179529Phase 2Completed
- Sponsor
- Technical University of Munich
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in atopic dermatitis (AD), sponsored by Technical University of Munich. Status: completed.
02
Drugs
omalizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01179529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01179529.